[CAS NO. 2086809-58-5] SRI-29329

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2086809-58-5]

Catalog

HY-123600

Brand

MCE

CAS

2086809-58-5

MDL	-
Molecular Weight	399.92
Molecular Formula	C20H26ClN7
SMILES	CC(N1C=NC2=C(NC3=CC=CC(Cl)=C3)N=C(N[C@H]4CCCC[C@@H]4N)N=C12)C

For research use only. We do not sell to patients.

SRI-29329 is a specific CLK inhibitor, with IC ₅₀ values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively ^[1] .

SRI-29329 (compound 8) shows some modest (~5 fold) selectivity for CLK2 over CLK1 and CLK4 without significant CDK1,4,6 activity ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Solid

Room temperature in continental US; may vary elsewhere.

In Vitro:

DMSO : 50 mg/mL ( 125.03 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (6.25 mM); Suspended solution; Need ultrasonic

* All of the co-solvents are available by MCE.